The Food and Drug Administration yesterday announced safety labeling changes for fluoroquinolone antibiotics to strengthen warnings about the risk of mental health side effects and serious blood sugar disturbances. Based on a recent FDA review of adverse event reports and the medical literature, the updated labeling will highlight mental health side effects including disturbances in attention, disorientation, agitation, nervousness, memory impairment and delirium, and the potential risk of coma with hypoglycemia. Fluoroquinolone antibiotics are used to treat certain serious bacterial infections.
 

Related News Articles

Headline
The AHA today submitted to the Food and Drug Administration legislative, regulatory and best practice recommendations to address new and chronic prescription…
Headline
A coalition of 40 health care and public health organizations, including the AHA, today urged the Senate to quickly pass the Pandemic and All-Hazards…
Headline
The House of Representatives last night passed legislation (H.R. 269) that includes the Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary of Preparedness and Response will host a Jan. 29 webinar on its new toolkit.
Insights and Analysis
Reynolds says the Institute is poised to be a convener of the AHA’s diverse constituency and will elevate the relevance of its expertise and educational…
Headline
The Centers for Medicare…